Advertisement

Topics

BARCLAYS Company Profile

05:21 EDT 26th September 2017 | BioPortfolio

Nil

Contact

Email: internetsecurity@barclays.co.uk


News Articles [40 Associated News Articles listed on BioPortfolio]

Mylan Stock Gains Following Barclays Upgrade

Shares of Mylan were up 1.2% in morning trading Monday after analysts at Barclays upgraded the stock to "overweight" from "equal weight" while also raising its price target to $50 from $47. Barclays a...

Barclays senkt Ziel für IBM auf 132 Dollar - 'Underweight'

Die britische Investmentbank Barclays hat das Kursziel für IBM von 141 auf 132 US-Dollar gesenkt und die Einstufung auf "Underweight" belassen. Er habe seine bereits unter dem Konsens liegenden Sc...

McKesson Co. (MCK) Given a $187.00 Price Target by Barclays PLC Analysts

The firm presently has a "buy" rating on the stock. Barclays PLC's price objective indicates a potential upside of 12.85% from the stock's current price.

Barclays belässt Novartis auf 'Underweight' - Ziel 65 Franken

Die britische Investmentbank Barclays hat die Einstufung für Novartis nach der jährlichen Präsentation des Managements in Boston auf "Underweight" mit einem Kursziel von 65 Franken belassen. Analy....

Barclays hebt Ziel für Microsoft auf 82 Dollar - 'Overweight'

Die britische Investmentbank Barclays hat das Kursziel für Microsoft von 77 auf 82 US-Dollar angehoben und die Einstufung auf "Overweight" belassen. Dies schrieb Analyst Raimo Lenschow in einer St...

Barclays hebt Ziel für Roche auf 320 Franken - 'Overweight'

Die britische Investmentbank Barclays hat das Kursziel für Roche von 310 auf 320 Franken angehoben und die Einstufung auf "Overweight" belassen. Analyst Emmanuel Papadakis traut dem neuen MS-Antik...

Barclays hebt ExxonMobil auf 'Overweight' - Ziel 94 US-Dollar

Die britische Investmentbank Barclays hat ExxonMobil von "Equal Weight" auf "Overweight" hochgestuft, aber das Kursziel auf 94 US-Dollar belassen. Die Aktie sollte kurzfristig von der Führungsposi...

Barclays senkt Ziel für Roche auf 295 Franken - 'Overweight'

Die britische Investmentbank Barclays hat das Kursziel für Roche nach dem Jahreskongress europäischer Onkologen von 305 auf 295 Franken gesenkt, aber die Einstufung auf "Overweight" belassen. Die .....

Drugs and Medications [0 Results]

None

PubMed Articles [1 Associated PubMed Articles listed on BioPortfolio]

Planning for the Leicester City Football Club victory parade.

This paper details the multiagency planning for and delivery of the Leicester City Football Club victory parade at the end of the 2015/16 football season to celebrate the team winning the Barclays Pre...

Clinical Trials [0 Results]

None

Companies [4 Associated Companies listed on BioPortfolio]

BARCLAYS

Nil

Esay Solutions

eSAY develop answers for business problems. As a complete IT consultancy, we offer our clients the opportunity to improve their business through the application of tailored IT products. We have helped...

hblmedia

hbl media is a fast growing, London-based communications agency that specialises in helping companies and organisations to communicate their brand values through the media.Our approach to communicatio...

Veracode

Veracode is the only independent provider of cloud-based application intelligence and security verification services. The Veracode platform provides the fastest, mos...

More Information about "BARCLAYS" on BioPortfolio

We have published hundreds of BARCLAYS news stories on BioPortfolio along with dozens of BARCLAYS Clinical Trials and PubMed Articles about BARCLAYS for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of BARCLAYS Companies in our database. You can also find out about relevant BARCLAYS Drugs and Medications on this site too.

Quick Search
Advertisement
 

Corporate Database Quicklinks



Searches Linking to this Company Record